Also see: Adobe: Analysts' New RatingsEditor's Note: Green and red arrows refer to intraday stock price movement. NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES Amgen ( AMGN) price target cut at Credit Suisse to $55 from $58 on higher agency costs, Credit Suisse said. Maintain Neutral rating. American Express ( AXP) numbers lowered at Morgan Stanley. AXP estimates were cut through 2012, Morgan Stanley said. Company is investing in long-term growth. Overweight rating and new $51 price target. Bank of America ( BAC) estimates reduced at Morgan Stanley BAC estimates were cut through 2012, Morgan Stanley said. Company is facing higher private-label losses. Overweight rating and $22 price target. Comcast ( CMCSA) estimates, target raised at Morgan Stanley. Shares of CMCSA now seen reaching $25, according to Morgan Stanley. Estimates also increased, as the company is buying back more stock. Equal-weight rating. Costco ( COST) target boosted at UBS to $73. Company should continue to deliver above-average sales growth. Neutral rating. Fifth Third ( FITB) numbers raised at Citigroup. Shares of FITB now seen reaching $17. Estimates also increased, given better core loan trends. Hold rating. General Electric ( GE) numbers boosted at Oppenheimer. Shares of GE now seen reaching $23. Estimates also upped, given better industrial and GE Capital results. Outperform rating. Halliburton ( HAL) estimates upped at UBS through 2011. Company is seeing better sales and margins across the board. Buy rating and $48 price target. Halliburton ( HAL) added to Top Picks List at FBR. $72 price target. Company should continue to grow in the domestic land market. Henry Schein ( HSIC) numbers boosted at UBS. Shares of HSIC now seen reaching $72, according to UBS. Estimates also upped, as dental trends are improving. Neutral rating. Hospira ( HSP) estimates, target cut at Goldman. Shares of HSP now seen reaching $65, according to Goldman Sachs. Estimates also lowered, given delays for generic Taxotere. Buy rating. Johnson Controls ( JCI) numbers upped at Morgan Stanley. JCI estimates were boosted through 2013, Morgan Stanley said. Acquisitions are adding to earnings. Overweight rating and new $44 price target.